Twice-weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: Cohort study in rural South Africa

AIDS

Volumn 13, Issue 7, 1999, Pages 811-817

  Davies, Geraint R ^a   Connolly, Cathy ^d   Wim Sturm, A ^b   McAdam, Keith P W J ^d   Wilkinson, David ^a,b,c  

^a Hlabisa Hospital   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d NONE

Author keywords

Africa; HIV; Intermittent therapy; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMMUNITY CARE; DEATH; DRUG EFFICACY; DRUG RESISTANCE; EPIDEMIC; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; RURAL AREA; SMEAR; SOUTH AFRICA; TREATMENT OUTCOME;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; HUMANS; ISONIAZID; MALE; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PYRAZINAMIDE; RIFAMPIN; SOUTH AFRICA; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 0032950999     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199905070-00010     Document Type: Article

References (25)

1. 1. Raviglione M, Harries AD, Msiska R, Wilkinson D, Nunn P: AIDS in Africa. In Tuberculosis and HIV: current status in Africa, 2nd ed. Edited by Iaga M. London: Rapid Science Publications, 1997.
2. 2. De Cock KM, Soro B, Coulibaly IM, Lucas SB: Tuberculosis and HIV infection in sub-Saharan Africa. JAMA 1992, 268:1581-1587.
3. 3. Cantwell MF, Binkni NJ: Tuberculosis in sub-Saharan Africa: a regional assessment of the impact of the human immunodeficiency virus and National Tuberculosis Control Programme quality. Tubercle Lung Dis 1996, 77:220-225.
4. 4. World Health Organisation: Global tuberculosis control. Global tuberculosis programme. WHO/GTB/97.225. Geneva: World Health Organisation.
5. 5. De Cock KM, Wilkinson D: Tuberculosis control in resource-poor countries: alternative strategies in the era of HIV. Lancet 1995, 346:675-677.
6. 6. World Health Organisation: Treatment of tuberculosis: Guidelines for national programmes, 2nd ed. Geneva: World Health Organisation; 1992.
7. 7. Chan SI: Chemotherapy of tuberculosis. In Clinical tuberculosis, 1st ed. Edited by Davies PDO. London: Chapman and Hall; 1994:141-156.
8. 8. Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA: A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis: a twice weekly, directly observed and cost-effective regimen. Ann Intern Med 1990, 112:407-415.
9. 9. Caminero JA, Pavon JM, Rodriguez de Castro F, Diaz F, Julia G, Cayla JA, Caberra P: Evaluation of a directly observed six months fully intermittent treatment regimen for tuberculosis patients suspected of poor compliance. Thorax 1996, 51:1130-1133.
10. 10. Chaisson RE, Clermont HC, Holt EA, et al.: Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996, 154:1034-1038.
11. 11. Wilkinson D: High compliance tuberculosis treatment programme in a rural community. Lancet 1994, 343:647-648.
12. 12. Floyd K, Wilkinson D, Gilks CF: Comparison of cost effectiveness of directly observed treatment (DOT) and conventionally delivered treatment for tuberculosis: experience from rural South Africa. BMJ 1997, 315:1407-1411.
13. 13. Wilkinson D, Davies GR, Connolly C: Directly observed therapy for tuberculosis in rural South Africa, 1991 through 1994. Am J Public Health 1996, 86:1094-1097.
14. 14. Wilkinson D, Davies GR: Coping with Africa's increasing tuberculosis burden: are community supervisors an essential part of the DOT strategy? Trop Med Int Health 1997, 2:700-704.
15. 15. Hopewell P, Cynamon M, Starke J, Iseman M, O'Brien R: General guidelines for the evaluation of new antimicrobial drugs for the treatment of systemic mycobacterial infections. Clin Infect Dis 1992, 15 (Suppl.):S282-295.
16. 16. Wilkinson D, Wilkinson NF, Lombard C, et al.: On-site HIV testing in resource-poor settings: is one rapid test enough? AIDS 1997, 11:377-381.
17. 17. Wilkinson D, Anderson E, Davies GR, Sturm AW, McAdam KPWJ: Efficacy of twice-weekly treatment for tuberculosis given under direct observation in Africa. Trans R Soc Trop Med Hyg 1997, 91:87-89.
18. 18. Wilkinson D, Pillay M, Davies GR, Sturm AW: Resistance to antituberculosis drugs in rural South Africa: rates, patterns, risks, and transmission dynamics. Trans R Soc Trop Med Hyg 1996, 90:692-695.
19. 19. Githui W, Nunn P, Juma E, Karimi F, Brindle R, Makunyi R, et al.: Cohort study of HIV positive and HIV negative tuberculosis, Nairobi, Kenya: comparison of bacteriological results. Tubercle Lung Dis 1992, 73:203-209.
20. 20. Elliott AM, Halwiindi B, Hayes RJ, Luo N, Mwinga AG, Tembo G, et al.: The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis: two-year follow-up of a cohort in Lusaka, Zambia. J Trop Med Hyg 1995, 98:9-21.
21. 21. Kassim S, Sassan-Morokro M, Ackah A, et al.: Two-year follow up of persons with HIV-1 and HIV-2-associated pulmonary tuberculosis treated with short course chemotherapy in West Africa. AIDS 1995, 9:1185-1191.
22. 22. Perriens JH, St Louis ME, Mukadi YB, Brown C, Prignot J, Pouthier T, et al.: Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995, 332:779-784.
23. 23. Wilkinson D: Intermittent and directly observed chemotherapy: the sensible therapeutic option in the treatment of tuberculosis. In Bailliere's clinical infectious diseases. Mycobacterial diseases part 1: clinical frontiers. Edited by Malin A, McAdam KPWJ. London: Bailliere Tindall; 1997.
24. 24. Wilkinson D, Bechan S, Connolly C, Standing E, Short GM: Should we take a history of prior treatment, and check sputum status at 2-3 months when treating patients for tuberculosis? Int J Tuberc Lung Dis 1998, 2:52-55.
25. 25. Volmink J, Garner P: Promoting adherence to tuberculosis treatment. In Infectious diseases module of the Cochrane database of systematic reviews (updated 2 December 1997). Edited by Garner P, Gelband H, Olliaro P, Salinas R, Volmink J, Wilkinson D. Available in The Cochrane Library (database on disk and CD ROM). The Cochrane Collaboration, issue 1. Oxford: Update Software; 1998. Updated quarterly.